GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung (NCT07679607)
🩺 Plain-English Summary (8th-Grade Level)
Decreased respiratory function is a common side effect experienced by non-small cell lung cancer (NSCLC) patients who receive radiation therapy. In current clinical practice when treating cancerous lesions in the lung, it is not standard to explicitly try and avoid excessive radiation dose and therefore radiation injury to smaller airways. However, because of this patients may obtain damage to an airway segment can cause downstream regions in the lung to lose their "supply line" and, therefore, cause patients to lose the ability to exchange oxygen with the blood. The purpose of this clinical trial is to systematically compare post-treatment lung function of those who receive regular clinical radiation therapy (standard of care \[SoC\]) versus those who receive the airway-sparing radiation therapy regimen. The investigators hope to show that, by preserving airways and connected lung regions, participants will be able to retain a larger amount of their lung function, which will have a direct, positive impact on their post-treatment quality of life.
Who can join: Review the eligibility criteria below.
Location: University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
Age range: 18 Years
🧪 Interventions in This Study
- SOC Radiation Treatment Planning (RADIATION)
- INSPIRE Radiation Treatment Planning (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
📞 Contact the Study Coordinator
Phone: (410) 328-6080
Email: asawant@som.umaryland.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer (NSCLC)
- Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 — Detroit, Michigan
- A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors — Orlando, Florida
- Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer — Kingsport, Tennessee
- A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. — Cincinnati, Ohio
- Engagement of Veterans With Lung Cancer — Palo Alto, California
Explore by condition: All Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.